A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Sarker D, Dawson NA, Aparicio AM, Dorff TB, et al. Clin Cancer Res 2021 Jul 19. pii: 1078-0432.CCR-21-1115.

Read + Share

Amedeo Smart

Independent Medical Education